Drug Trial Radar · NCT00061633
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Last checked: Nov 19, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Jun 2003
Primary completion
Jan 2004
Study completion Jan 2004
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control infections and whether this drug can be safely given to patients.
Conditions
- Infections, Gram-Positive Bacterial
- Abscess
- Burns
- Cellulitis
- Ulcer
- Wound Infections
Interventions
TelavancinDrug
Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
Vancomycin or antistaphylococcal penicillinDrug
Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) PopulationTime frame: 7-14 days following end of antibiotic treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
eStudy Site, 3450 Bonita Road, Ste 201
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.